Quest Partners LLC Acquires 24,817 Shares of Artivion, Inc. (NYSE:AORT)

Quest Partners LLC boosted its stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 2,481,700.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,818 shares of the company's stock after purchasing an additional 24,817 shares during the quarter. Quest Partners LLC owned approximately 0.06% of Artivion worth $661,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Artivion by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company's stock valued at $56,388,000 after purchasing an additional 33,982 shares during the period. First Eagle Investment Management LLC boosted its position in Artivion by 4.9% during the 2nd quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company's stock valued at $15,342,000 after purchasing an additional 27,906 shares during the period. Tidal Investments LLC acquired a new position in Artivion during the 1st quarter valued at approximately $257,000. Price T Rowe Associates Inc. MD boosted its position in Artivion by 5.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company's stock valued at $713,000 after purchasing an additional 1,634 shares during the period. Finally, Perceptive Advisors LLC boosted its position in Artivion by 4.7% during the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company's stock valued at $71,658,000 after purchasing an additional 124,725 shares during the period. Institutional investors and hedge funds own 86.37% of the company's stock.

Artivion Trading Up 0.9 %

Shares of Artivion stock traded up $0.24 on Friday, reaching $28.27. 222,367 shares of the company were exchanged, compared to its average volume of 231,457. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -1,413.25 and a beta of 1.75. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The stock has a fifty day moving average price of $26.62 and a 200-day moving average price of $25.60. Artivion, Inc. has a fifty-two week low of $16.48 and a fifty-two week high of $30.00.

Analyst Ratings Changes

A number of brokerages have issued reports on AORT. Needham & Company LLC reiterated a "buy" rating and set a $30.00 price target on shares of Artivion in a research report on Friday, September 27th. Stifel Nicolaus boosted their price target on Artivion from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, September 13th. Oppenheimer boosted their price target on Artivion from $30.00 to $32.00 and gave the stock an "outperform" rating in a research report on Friday, November 8th. Finally, JMP Securities started coverage on Artivion in a research note on Wednesday, October 23rd. They issued an "outperform" rating and a $33.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Artivion has an average rating of "Buy" and an average target price of $31.00.

Insider Activity

In related news, CAO Amy Horton sold 12,430 shares of the company's stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now directly owns 139,989 shares of the company's stock, valued at approximately $3,664,912.02. This represents a 8.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jean F. Holloway sold 3,167 shares of the company's stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.55, for a total value of $84,083.85. Following the transaction, the senior vice president now directly owns 161,932 shares in the company, valued at approximately $4,299,294.60. This trade represents a 1.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.10% of the stock is owned by company insiders.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.